BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) Form 10-Q — Aug 10, 2026
BioForce Nanosciences' 10-Q for the quarter ended June 30, 2026 shows zero revenue, just $307 in cash, an accumulated deficit of $162.3 million, and substantial doubt about its ability to continue as a going concern. Six-month net income of $136,271 was driven entirely by a $502,373 debt forgiveness from director Merle Ferguson rather than by operations.
Key figures
- Eps
- 0.01 (Q2 2026 basic/diluted); 0.00 (six months 2026)
- Revenue
- 0
- Net Income
- 136271
- Total Assets
- 2388075
- Cash Position
- 307
- Shares Outstanding
- 33549005
- Lease acres
- 19957
- Stock payable
- 2484300
- Prepaid expenses
- 2153243
- Total liabilities
- 84767
- Q2 2026 net income
- 238682
- Federal royalty pct
- 12.5
- Stockholders equity
- 2303308
- Lease carrying value
- 234525
- Control sale price usd
- 400000
- Control stake sold pct
- 79.65
- Federal oil gas leases
- 11
- Legal settlement income
- 15322
- Debt forgiveness ferguson
- 502373
- Shares sold in control change
- 26700000
- Blm transfer fee per claim usd
- 120
- Restricted share reference price
- 0.55
AI analysis
Red flags9 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.